BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
As of 02:12PM EDT. Market open.
| Previous close | 90.07 |
| Open | 89.67 |
| Bid | 88.72 x 100 |
| Ask | 88.83 x 100 |
| Day's range | 88.60 - 90.18 |
| 52-week range | 76.02 - 99.56 |
| Volume | |
| Avg. volume | 1,403,309 |
| Market cap | 16.852B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 102.07 |
| EPS (TTM) | 0.87 |
| Earnings date | 24 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 109.70 |
ZacksEarnings Preview: Bristol Myers Squibb (BMY) Q1 Earnings Expected to Decline
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ZacksBioMarin Pharmaceutical (BMRN) Expected to Beat Earnings Estimates: Should You Buy?
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GuruFocus.comInsider Sell: Biomarin Pharmaceutical Inc (BMRN) Chief Accounting Officer Erin Burkhart ...
Biomarin Pharmaceutical Inc (NASDAQ:BMRN), a global biotechnology company focused on developing and commercializing innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases, has reported an insider sell according to a recent SEC filing.
© 2024 Yahoo. All rights reserved.